Searching journal content for BRCA2 (as phrase) in full text.

Displaying results 1-10 of 99
For checked items
  1. ...BRCA2 enhances cisplatin and cisplatin-induced autophagy in ovarian 1 cancer cells 2 BRCA2 modulates chemotherapy sensitivity 3 Biao Wan , Leheyi Dai , Li Wang , Ying Zhang , Hong Huang , Guanhua Qian , Tinghe Yu Key Medical Laboratory of Obstetrics and Gynecology, The Second Affiliated Hospital, 5 ~~~
  2. ...BRCA2 mutation carriers, Kotsopoulos et al. (2012) observed a significant decrease in the risk of breast cancer in women who are oophorectomized after menopause than that in women in natural menopause and suggested that the reduction of circulating testosterone levels after oophorectomy might accoun ~~~
  3. ...BRCA2 Fanconi anemia 227650 CIN Leukemia FANCA Head and neck cancer FANCB Brain tumors FANCC Wilms tumor FANCD1 (BRCA2) Breast cancer FANCD2 Pancreatic cancer FANCE FANCF FANCG FANCI FANCJ (BRIP1) FANCL FANCM FANCN (PALB2) FANCO (RAD51C) FANCP (SLX4) FANCQ (ERCC4) FANCS (BRCA1) FANCR (RAD51) FANCT ( ~~~
  4. ...BRCA2 gene (1 individual out of 98) and in the DNA damage repair gene CHEK2 (4 individuals out of 98) (Scarpa et al. 2017). All these PanNET were apparently sporadic and no data on penetrance of these germline mutations in PanNET are available. All tumours showed mutation profiles typical for repair ~~~
  5. ...BRCA2 (breast cancer susceptibility gene 2) heterozygous epithelial breast cells due to irradiation NCT00773695 Interventional Hoffmann-La Roche A multicenter, randomized, ph II clinical trial to evaluate the effect of avastin in combination with neoadj treatment regimens on the molecular and metabo ~~~
  6. ...BRCA2 germline mutation frequency (Johannson et al. 2014, Silvestri et al. 2016 )). This indicates additional molecular features may differentiate between genders, potentially leading to additional or new treatments for male breast cancer. The vast majority of male breast cancers express AR ( Murphy ~~~
  7. ...BRCA2 (Lord & Ashworth 2012). Several evidence suggests that the benefit of PARP inhibitors is not restricted to germline BRCA1/2 mutants and could be associated with a wider range of disrupted mechanisms. Hence, efforts have focussed on establishing a refined BRCAness signature (molecular signature ~~~
  8. ...BRCA2 genes (Nielsen & van Overeem Hansen 2016), the wellknown tumor suppressors that were identified by linkage analysis in the mid-1990s (Miki et al. 1994, Wooster et al. 1995). The lifetime risk of developing breast or ovarian cancer can be up to ~80% in these affected individuals. Mutations in B ~~~
  9. ...BRCA2 risk modifiers 10.1530/ERC-16-0277 Roger L Milne1,2 and Antonis C Antoniou3 1Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Australia 2Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, Victoria, Aus ~~~
  10. ...BRCA2 tumour suppressor genes were identified in the early 1990s, the immediate implications of mapping, cloning and delineating the sequence of these genes were that individuals in families with a BRCA gene mutation could be tested for the presence of a mutation and their risk of developing cancer ~~~
For checked items